ESCAPE: Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Study Details
Study Description
Brief Summary
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a prospective, multicenter, nonrandomized single-arm study assessing the diagnostic accuracy of PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) in determining the absence of clinically significant prostate cancer in patients on active surveillance (AS).The trial will enroll 200 subjects for low and favorable intermediate-risk prostate cancer patients per NCCN guidelines who have elected to pursue active surveillance.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: PSMA-PET CT Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point. |
Diagnostic Test: PSMA-PET CT
Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
|
Outcome Measures
Primary Outcome Measures
- Negative predictive value (NPV) [Baseline]
Negative predictive value (NPV): The NPV is defined as the number of negative image results with identified clinically insignificant prostate cancer on biopsy divided by the number of negative image results.
- Negative predictive value (NPV) [12 months]
Negative predictive value (NPV): The NPV is defined as the number of negative image results with identified clinically insignificant prostate cancer on biopsy divided by the number of negative image results.
- Negative predictive value (NPV) [24 months]
Negative predictive value (NPV): The NPV is defined as the number of negative image results with identified clinically insignificant prostate cancer on biopsy divided by the number of negative image results.
Secondary Outcome Measures
- Positive predictive value (PPV) of PSMA PET. [Baseline]
PPV of PSMA PET. Positive predictive value (PPV): The PPV is defined as the number of positive image results with identified csPCa on biopsy divided by the number of positive image results.
- Positive predictive value (PPV) of PSMA PET. [12 months]
PPV of PSMA PET. Positive predictive value (PPV): The PPV is defined as the number of positive image results with identified csPCa on biopsy divided by the number of positive image results.
- Positive predictive value (PPV) of PSMA PET. [24 months]
PPV of PSMA PET. Positive predictive value (PPV): The PPV is defined as the number of positive image results with identified csPCa on biopsy divided by the number of positive image results.
- Number of patients with negative PSMA pet scan. [Baseline]
- Number of patients with negative PSMA pet scan. [12 months]
- Number of patients with negative PSMA pet scan. [24 months]
- Number of positive scans on mpMRI [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on mpMRI [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on mpMRI [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on PSMA-PET [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on PSMA-PET [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on PSMA-PET [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on both PSMA-PET and mpMRI [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on both PSMA-PET and mpMRI [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of positive scans on both PSMA-PET and mpMRI [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Sensitivity: The sensitivity will be defined as the number of positive image results with a csPCa upon biopsy divided by the number of biopsied patients with csPCa following the imaging.
- Number of negative scans on mpMRI [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on mpMRI [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on mpMRI [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on PSMA-PET [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on PSMA-PET [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on PSMA-PET [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on both PSMA-PET and mpMRI [Baseline]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on both PSMA-PET and mpMRI [12 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of negative scans on both PSMA-PET and mpMRI [24 months]
Specificity and sensitivity of PSMA-PET, mpMRI, and the combination. Specificity: The specificity is defined as the number of negative image results followed by the absence of csPCa in the corresponding biopsy divided by the number of biopsies that did not identify csPCa.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by PSMA-PET. [Baseline]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by PSMA-PET. [12 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by PSMA-PET. [24 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by mpMRI. [Baseline]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by mpMRI. [12 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected by mpMRI. [24 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected on PSMA-PET and mpMRI. [Baseline]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected on PSMA-PET and mpMRI. [12 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
- Number of patients who have clinically significant Prostate Cancer (csPCa) detected on PSMA-PET and mpMRI. [24 months]
The proportion of csPCa detected by PSMA-PET, mpMRI, and the combination. Proportion of patients with csPCa: this will be the number of patients identified as having csPCa divided by the number of patients with a biopsy.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males aged ≥ 18.
-
Histologically confirmed low or favorable intermediate risk prostate cancer per NCCN guidelines. (Note: Grade Group 2 must have 20% or less involvement in every core and no presence of cribiform or intraductal carcinoma).
-
PSA < 20 ng/ml.
-
Ability to undergo yearly PSMA-PET CT.
-
Ability to undergo yearly prostate mpMRI.
-
Ability to undergo transrectal or transperineal template and fusion prostate biopsy.
-
Ability to complete HRQOL surveys (EPIC, IPSS, IIEF-5).
-
Willingness to undergo yearly prostate biopsies.
Exclusion Criteria:
-
History of prior treatment for prostate cancer.
-
History of systemic therapy for prostate cancer.
-
Inability to undergo transrectal ultrasound.
-
Life expectancy less than 10 years.
-
Not interested in pursuing active surveillance.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA | Los Angeles | California | United States | 90005 |
| 2 | UCSF | San Francisco | California | United States | 94143 |
| 3 | Case Western University Hospitals | Cleveland | Ohio | United States | 44106 |
| 4 | UT Southwestern | Dallas | Texas | United States | 75390 |
Sponsors and Collaborators
- Weill Medical College of Cornell University
Investigators
- Principal Investigator: Timothy Mcclure, M.D., Weill Medical College of Cornell University
- Principal Investigator: Himanshu Nagar, M.D., Weill Medical College of Cornell University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 23-03025893